Members

I am working in nano drug design field in Altınbaş University , Faculty of Pharmacy.

I have also 7 years of drug development experience in ARGEFAR R&D Center in EGE University.

My goal is to use nanoformulations that we developed for enhancing bioavailability. I also use these formulations for fluorescent imaging and to diminish side effects. I have previous experience in olmesartan medoxomil SMEDDS and Dexamethasone SNEDDS ophtalmic gtt. I also aim to design new formulations with this technology for miRNA's and vaccines.

I am looking forward to meeting with possible partners for nano drug development projects, who has bioavailability, side effect and drug targeting problems. Then we can provide solutions and publish our findings.

Eligibility criteria Researchers in R&D fields from universities, public or private sector.

Targeted gene silencing drugs project The University of Texas MD Anderson Cancer Center Prof.Dr. Bülent Özpolat

Anti-Cancer triple hit: MSLN, MYCN and Telomerase  targeting RNAs EuroNanoMed III 2021 Call (1st Phase) TÜBİTAK 1071, TÜBİTAK PROJECT, Director: YELDA KOMESLİ, Researcher: FATMA TUBA GÖZET, , 17/02/2021 ( Ongoing) (INTERNATIONAL)

Ege University Scientific Research Project (BAP), 2000, Master Thesis Project, Ph.D.Yelda Komesli, Prof.Dr. Levent                 Kirilmaz,  Studies on Responsive Drug Release Systems 99, 99 / ECZ / 014

Ege University Scientific Research Research Project (BAP), 2015, PhD Thesis Project, Prof.Dr. Ercüment Karasulu,

Exp. Pharm. Yelda Komesli ’Preparation of self-microemulsion drug delivery system (smedds) containing Olmesartan Medoxomil, In Vitro Quality Control, In Vivo Pharmacokinetics (by fluorescent Labeling) and Pharmacodynamic Evaluation 15’, 15-ECZ-014

Aliye Üster Foundation Project Achievement Scholarship, Preparation of Self-Emulsifying Drug Release System (SMEDDS) Containing Olmesartan Medoxomil, In Vitro Quality Control, In Vivo Pharmacokinetics (Via Fluorescent Marking) and Pharmacodynamic Evaluation, 2016

TÜBİTAK 3501 Career Development Project  Development of New Formulation of Olmesartan Medoxomil Containing Self-Emulsifying Microemulsion Drug Release System (SMEDDS) for Pediatric, Geriatric and Adult Patients, Evaluation of Pharmacokinetic Profile and Celiac-Like Enteropathy Side Effect. “C ‘’ score was given and the appropriation was not given. The appeal was rejected. 2018.

TÜBİTAK 1001 The Evaluation of the Pharmacokinetic Profile and Celiac-Like Side Effects of Self Microemulsifying Drug Delivery System (SMEDDS) and tablet of Olmesartan Medoxomil and Development of the Alternative Formulations for the Pediatric, Geriatric, and Adult Patients. 2019  (in the application process)

Altınbaş University BAP Project  “Ocular Targeting with Nanoparticular Lipid Based Systems as an Alternative of Intravitreal Injection”

Quantitative Analysis of Phenolic Compounds in Sage and Hawthorn Capsules by HPLC-UV Method, Scientific research project supported by Higher Education Institutions, Researcher: KOMESLİ YELDA, Director: GÖZET FATMA TUBA, , 15/05/2020 (Continuing) (ULUSAL) Altınbaş University BAP Project

1512 -Technoventure Capital Support Program (BiGG) Project titled "Enhancing Bioavailability of Olmesartan with Microemulsified Drug Release Systems (AREGEMENT)" Executive Yelda KOMESLİ (In Evaluation Phase)